

## Innovation Interlude: Molecular Imaging in Cardiology



Jonathan R. Lindner, M.D.  
M. Lowell Edwards Professor of Cardiology  
Knight Cardiovascular Institute  
Oregon National Primate Research Center  
Oregon Health & Science University

### Disclosures

Off-label use of contrast agents


Investigator initiated Grants from GE Healthcare, Astellas and Bracco

## Celestial Doppelgangers and Relativity

Hubble Telescope




QSO 0957+561  
“Twin Quasar”




## ***The Evolution of Cardiovascular Imaging***


### **Structure**



### **Function**



### **Metabolism/Perfusion**



## ***Molecular Imaging in Cardiology***

### Atherosclerosis – detection and risk

- |                 |                                    |
|-----------------|------------------------------------|
| -Inflammation   | -Protease activity                 |
| -Platelets, VWF | -Oxidative stress, oxidized lipids |
| -Vasa vasorum   | -TF, fibrin                        |

### Angiogenesis/Regenerative Biology

- |                                    |                      |
|------------------------------------|----------------------|
| -chemokines and growth factors     | -endothelial markers |
| -Stem cell recruitment/engraftment |                      |

### Ischemia

- Selectins, hypoxic metabolism, C' receptors

### Myocarditis/OHT rejection

- Adhesion molecules, inflammatory cells, chemokines, apoptosis

### Ventricular remodeling

- Protease activity, inflammatory cells, apoptosis




### Arrhythmogenesis

- |                       |                     |
|-----------------------|---------------------|
| -Sympathetic activity | -cell jxn molecules |
|-----------------------|---------------------|

## ***Examples of Strategies Used for Molecular Imaging***



1. Ligand-receptor binding which produces tracer retention or altered kinetics
2. Cellular retention from metabolic uptake or incorporation into metabolic machinery
3. Tracer activation by targeted metabolic or enzymatic process
4. Endogenous signal characteristics without contrast agent

## ***Microbubbles for Perfusion Imaging***



## **MB Targeting by Surface Targeting Ligand**

rPSGL-1 or  
Other targeting ligand



## **Roles for Molecular Imaging**

Basic Research & Discovery



Pre-clinical & Clinical Research



Clinical Medicine



Uncovering pathophysiology

Rapid evaluation of new therapies

Early diagnosis

Phenotyping animal models of disease

Optimization of therapies

More definitive diagnosis

Matching molecular process to anatomy or function

Evaluating mechanism of therapy or off target effects

Evaluating response to therapy

Matching gene expression to molecular or anatomic phenotype

Tracking cell or gene therapy

Customized therapy


Understanding resistance to disease

Monitoring disease progression or prognosis

## **Potential Clinical Roles of Molecular Imaging in Ischemia**



- Early detection of infarction *and* ischemia
- Risk stratification based on spatial extent of ischemia
- Detection of ischemia/infarction in those with pre-existing perfusion or wall motion abnormalities
- Salvaging the disaster stress echo.

## **Imaging Strategy and Temporal Resolution**




## Myocardial Ischemic Memory Imaging

### Anaerobic Metabolism - BMIPP-SPECT







Mochizuki T, et al. Ann Nucl Med 2002;16:563



Aras O, et al. Curr Opin Biotechnol 2007;18:46–51

## P-Selectin Targeting for Ischemic Memory







## **Potential Clinical Roles of Molecular Imaging in Atherosclerosis**

- Early detection of aggressive disease
- Vulnerability to complication (plaque or patient)
- Selection/optimization of therapy
- Pre-clinical drug development and early clinical proof-of-mechanism studies

## **Molecular Imaging in Atherosclerosis: Potential Targets**




## Aortic FDG-PET Activity For Prediction of Events







Figueroa AL, et al., JACC-CVI 2013;6:1250

## Plaque Development in LDL-R<sup>-/-</sup> and Apobec-1<sup>-/-</sup> mice




### Endothelial Phenotype in Insulin Resistance




Chadderton S, et al., Circulation 2014;129:471

### Platelets in “Non-ACS” Atherosclerosis

#### Scanning EM





#### Immunohistochemistry




1. Source for pro-inflammatory cytokines
2. Contribute to monocyte recruitment
3. Source for vasoconstrictor mediators
4. Source for pro-angiogenic cytokines and GFs




## Plt-Endothelial Interactions in DKO Mice



## Molecular Imaging of Platelet-Endothelial Interactions




VWF active A1 domain  
(AA 445-909)



Shim CY, et. al. Circ CV Imag 2015;8:e002765

### Imaging Treatment Effects with NOX Inhibition



Liu Y, et al,  
Circ CV Imaging 2013;6:74

